Abstract 18509: The Distribution and Characteristics of Endogenous Cardiac Stem Cells in All Four Chambers of the Adult Human Heart
Introduction: The adult myocardium, including human, harbours a population of resident (endogenous) multi-potent cardiac stem cells (eCSCs). We evaluated the distribution, stem cell properties, differentiation potential and effect of LV function on eCSCs in all 4 chambers of the human heart.
Methods: Myocardial biopsies from the RA, RV, LA and LV were taken from the same patient with good LV function (EF>45; n=5) or those with impaired LV function (EF<45; n=5). Cross sections were analysed for tryptaseneg, c-kitpos and MDR-1pos eCSCs. CD45neg, CD31neg and c-kitpos . eCSCs were isolated using MACS technology from 10 further patients (Good and Impaired LV, n=5/group) and assessed for clonogenicity, proliferation, sphere formation and differentiation potential.
Results: In good LV patients, the number of eCSCs in the RA was decreased (6±1 eCSCs/mm2; p<0.05) compared to the RV, LA and LV (28±10 eCSCs/mm2). In impaired LV patients, the number of eCSCs were increased (p<0.05) in LA and LV (32±0.2 and 37±3 eCSCs/mm2), compared to RA and RV (27±1 and 29±3 eCSCs/mm2). eCSCs isolated from the LV showed increased (p<0.05) proliferation and sphere formation, compared to the other chambers. There was no significant difference in eCSC clonogenicity or cardiac differentiation potential between chambers. Overall, the number of eCSCs was increased (p<0.05) in impaired LV patients, compared to good LV patients, however there was no significant difference between good and impaired LV patients for eCSC proliferation, sphere formation, clonogenicity or differentiation potential.
Conclusions: eCSCs isolated from the LV chamber show improved proliferation and sphere formation, compared to eCSCs isolated from the other chambers. Hearts with impaired LV function show increased number of eCSCs, however the ability of eCSCs to proliferate, generate single-cell clones, spheres and differentiate into the cardiac lineage is unaffected by differences in LV function.
- Regenerative medicine stem cells
- Stem/progenitor cells
- Cardiac development
- Cardiovascular disease
Author Disclosures: S. Sarvananthan: None. F.C. Lewis: None. G. Gritti: None. B.J. Henning: None. N. Latif: None. P. Sarathchandra: None. M. Yacoub: None. S.E. Harding: None. P.P. Punjabi: None. G.M. Ellison-Hughes: None.
- © 2016 by American Heart Association, Inc.